Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc and Bristol-Myers Squibb Company.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-453-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.15 million
Profitability
Miscellaneous
Employees25
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) issued its earnings results on Tuesday, July, 30th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The biotechnology company earned $0.26 million during the quarter, compared to analysts' expectations of $2.60 million. Infinity Pharmaceuticals had a negative net margin of 77.80% and a negative return on equity of 42.16%. View Infinity Pharmaceuticals' Earnings History.
When is Infinity Pharmaceuticals' next earnings date?
What price target have analysts set for INFI?
6 equities research analysts have issued twelve-month target prices for Infinity Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $3.00 in the next year. This suggests a possible upside of 158.6% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.
What is the consensus analysts' recommendation for Infinity Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Infinity Pharmaceuticals.
Has Infinity Pharmaceuticals been receiving favorable news coverage?
Headlines about INFI stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Infinity Pharmaceuticals.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Seres Therapeutics (MCRB), Zynerba Pharmaceuticals (ZYNE), OptiNose (OPTN), Cyclerion Therapeutics (CYCN), Flex Pharma (FLKS), NuCana (NCNA), Aratana Therapeutics (PETX), TapImmune (MRKR), Evofem Biosciences (EVFM), Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Verrica Pharmaceuticals (VRCA), Aeglea Bio Therapeutics (AGLE) and Chiasma (CHMA).
What other stocks do shareholders of Infinity Pharmaceuticals own?
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
- Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
- Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
- Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
- Ms. Melissa Hackel, VP of Fin.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.76%), Acadian Asset Management LLC (1.05%), JPMorgan Chase & Co. (0.38%), Jacobs Levy Equity Management Inc. (0.35%), Evercore Wealth Management LLC (0.25%) and Athanor Capital LP (0.17%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which institutional investors are selling Infinity Pharmaceuticals stock?
Which institutional investors are buying Infinity Pharmaceuticals stock?
INFI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Athanor Capital LP, Acadian Asset Management LLC, Parametric Portfolio Associates LLC, Evercore Wealth Management LLC and Jacobs Levy Equity Management Inc.. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $1.16.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $66.15 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.View Additional Information About Infinity Pharmaceuticals.
What is Infinity Pharmaceuticals' official website?
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
